OptiNose (NASDAQ:OPTN - Get Free Report) is set to issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. OptiNose has set its FY 2024 guidance at EPS.Parties interested in listening to the company's conference call can do so using this link.
OptiNose (NASDAQ:OPTN - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The business had revenue of $20.49 million during the quarter, compared to analysts' expectations of $20.81 million. On average, analysts expect OptiNose to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
OptiNose Price Performance
Shares of OPTN stock traded up $0.04 during mid-day trading on Wednesday, reaching $0.71. The stock had a trading volume of 380,220 shares, compared to its average volume of 712,563. The stock's 50-day moving average price is $0.80 and its two-hundred day moving average price is $0.97. OptiNose has a 52-week low of $0.65 and a 52-week high of $2.10.
OptiNose Company Profile
(
Get Free Report)
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
See Also
Before you consider OptiNose, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptiNose wasn't on the list.
While OptiNose currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
